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1. Abstract 
Background 
New recommendations for rabies postexposure prophylaxis (rPEP) were published by 
the Centers for Disease Control and Prevention and the World Health Organization in 
2010. In view of these new recommendations, the adequacy of rPEP among patients 
consulting the travel clinic of the University Hospital of Lausanne has been 
investigated and 6,8% of patients have been identified as non-responders with the new 
rPEP regimen. In this study we have selected the non-responders for a complete 
immunologic work up. 
 
Method 
Clinical and paraclinical immunologic investigations have been done to the non-
responders patients. Those investigations have been conducted to look for an 
increased susceptibility to infections and an immunodeficiency. The investigations 
included a clinical evaluation, a full blood count, measurement of the 
immunoglobulin levels, a numeration of the subpopulations of the lymphocytes, a 
HIV test and an evaluation of the humoral response to tetanus, pneumococcal, and 
hepatitis B vaccinations. A lymphocyte proliferation assay with rabies antigen was 
performed to assess the cellular immune response. 
 
Results 
9 subjects with rabies antibody titers ≤0,5 IU/ml after an rPEP with 4 doses were 
included in this study (=non-responders). 8/9 of these non-responders had an 
unremarkable medical history. 9/9 of them had normal paraclinical tests that did not 
suggest an immunodeficiency. The results of the lymphocyte proliferation assay with 
rabies antigen showed a significant correlation between the level of the humoral and 
cellular response. 
 
Conclusion 
These results suggest that a 4 dose intramuscular rPEP elicits in some patients a 
relatively poor humoral and cellular response, even in the absence of any 
immunosuppression. A serology on day 21 of the rPEP seems therefore useful to 
identify the patients who don't respond appropriately.  Those non-responders should 
receive additional doses until they reach an antibody titer above 0.5 IU/ml. 
 
 
 
2. Introduction 
 Despite the fact that most countries in the Western Hemisphere have 
succeeded in eliminating rabies transmitted by terrestrial animals, the disease remains 
endemic in numerous developing countries.i Rabies remains especially widespread in 
most African and Asian countries and causes an estimated 60,000 human rabies-
related deaths worldwide each year.ii 
 After potential rabies exposure, a rabies post-exposure prophylaxis (rPEP) is 
recommended. It involves active immunization and administration of rabies 
immunoglobulins for non-immune patients. One of the most widely used regimens for 
rPEP has been the Essen regimen, which includes five doses of intramuscular vaccine 
on days 0, 3, 7, 14 and 28 after exposure and a serological test on day 21 to verify the 
adequacy of the immune response. A rabies-specific antibody titer > 0,5 IU/ml 
measured by the rapid fluorescent focus inhibition test (RFFIT) has usually been 
considered as adequate. Many years of use and many studies have merely confirmed 
the effectiveness of this regimen.iii 
 In 2010 the Center of Disease Control (CDC) and the World Health 
Organization (WHO) published new recommendations for rPEP.iv, v These 
recommendations were to reduce the number of doses for rPEP from 5 to 4, and to 
abandon the serological test on day 21. These recommendations were not only 
influenced by conclusions from research studies, but also by recurrent shortages of 
rabies vaccine and the fact that many developing countries were encountering 
difficulties in performing reliable serological testing by RFFIT. 
 Taking into account these new guidelines, we conducted previously an 
investigation about the adequacy of the humoral response in patients who consulted 
our institution between 2005 and 2011 for a rPEP.vi This study showed that 6.7% 
(6/90) of these patients had an anti-rabies antibody titer < 0.5 IU/ml after 4 doses. All 
these patients had an adequate increase of their rabies antibody titer after receiving 
additional vaccine doses. In an editorial, Henry Wilde suggested that those patients, 
who have not responded adequately to 4 doses of rPEP, suffered probably from a non-
recognized immunodeficiency. vii 
To verify this hypothesis, we performed an immunological work up in rPEP non-
responders. In addition we investigated the cellular immune response to rabies antigen 
in these subjects. 
3. Methodology 
3.1 Selection of subjects 
 All patients who had received a rPEP at the University Hospital of Lausanne 
between 2005 and 2014 and who had an anti-rabies antibody titers ≤ 0,5 IU/ml after 4 
doses of vaccine were contacted to be included in the study (= non-responders).  
 Two comparator groups were made to perform the experimental immunologic 
tests. The positive control group included 9 patients who had received a rPEP at the 
University Hospital of Lausanne between 2005 and 2014 and who had after 4 doses of 
vaccine an anti-rabies antibody titers > 1 IU/ml. A negative control group included 9 
healthy volunteers who had never received any rabies vaccine. 
 
3.2 Evaluation of subjects 
 The non-responders were seen for a consultation, which included a complete 
anamnesis and a physical examination. The anamnesis was focused to detect an 
increased susceptibility to infections.   
 Blood samples were taken to perform the following investigations: full blood 
count, measurement of IgA, IgM and IgG levels, as well as the 4 subclasses of IgG, 
numeration of lymphocyte subpopulations (CD4 cells, CD8 cells, B cells and NK 
cells), and an HIV test. 
 Evaluations of the humoral response to tetanus, pneumococcal, and hepatitis B 
vaccinations were performed. An assessment of tetanus antibody levels was 
performed in patients who had received a dose of tetanus vaccine in the last 10 years. 
A tetanus antibody level < 0.1 U/ml was considered as abnormal. An assessment of 
anti-HBs was performed in patients who had been vaccinated in the last 5 years, or 4 
weeks after receiving a fourth dose of hepatitis B vaccine. Undetectable anti-HBs 
levels were considered as abnormal. Patients who had never received pneumococcal 
vaccine in the past were proposed to receive one dose of the 23-valent polysaccharide 
anti-pneumococcal vaccine. 4 weeks later, the level of antibodies against serotypes 
9N, 11A, 14, 17F, 19F, 23F were assessed. An undetectable antibody level against 
more than 4 serotypes was considered abnormal (<0.3 mg/l) 
 
3.3 Assessment of cellular immune response 
 Following up the protocol for production, concentration, and titration of 
B19G- and EnvA- pseudotyped rabies virus, developed by Nicholas R. Wall, viii we 
performed a Peripheral blood mononuclear cell (PBMC) proliferation assay to our 
three groups of subjects. Successful PBMC assays have been made with inactivated 
cell culture vaccines in previous published studies, ix, x, xi and because of its successful 
use in a previous immunologic experience,xii we chose to perform our PBMC 
proliferation assay using the Flury-LEP strain Purified chick embryo cell (PCEC) 
rabies vaccine (Rabipur®). PBMC (250 000 cells per well in triplicates) were 
cultivated for 6 days in presence of rabies vaccine particles and positive controls, a 
mitogen (phytohemagglutinin, PHA) or recall antigens, or unstimulated. Cultures 
were exposed to tritiated thymidine (1 µCi per well) for 20h at the end of the culture. 
Cells’ DNA from each well was harvested on glass fiber plates and incorporated 
thymidine counted using a beta counter. Results were expressed as stimulation indices 
(SI = mean cpm in stimulated wells / mean cpm in unstimulated wells). 
 A series of preliminary PBMC proliferation experiments were performed for 
the settings of the stimulation with Rabipur and to assess the sensibility and the 
sensitivity of the assay. First, PBMC from two very good responders selected from 
our positive control group (PC6 and PC7), with anti-rabies antibody titers of 22.2 and 
16.4 IU/ml on the 21st day of their PEP schedule were cultivated in presence of a 
titration of the original Rabipur® single dose 2500 mIU/ml in its freshly reconstituted 
or defrosted form, starting from a dilution of 1:10, then 1:3, from 250 to 0.11 mIU/ml. 
Both subject had similar results with a peak response at a dose of Rabipur of 1:100 
(25 mIU/ml) and a decrease of their response with decreasing doses. However, even 
at the lowest concentration of 1:10000, their responses were still significant and the 
non-stimulating dose could be estimated at 1.35.10-4 mIU/ml for those two subjects.  
 Proliferation of PBMC from 2 non-vaccinated control subjects and 2 selected 
non-responders was then performed to evaluate the specificity and sensibility of the 
stimulation with Rabipur. The dose responses obtained permitted to determine 3 doses 
of Rabipur, 25, 2.5 and 0.25 mIU/ml for the further experiments. At this stage, a good 
correlation between proliferation and antibody levels from the 6 subjects evaluated 
was obtained with a Pearson factor of = 0.990. Moreover, as the response in our 
experimental tests were similar with the fresh and defrosted Flury-LEP strain, we 
conducted all subsequent experiments with the defrosted  Rabipur® strain, due to its 
availability.  
 To complete our investigations and be able to set a comparative immunologic 
response analysis, our subjects were also tested for their memory response, using a 
recall antigen preparation (Memory mix, MM) containing tetanus toxoid (TT), 
purified protein derivative (PPD) from Mycobacterium tuberculosis and Candida 
mannan antigens. In addition, their non-specific cellular immunity was tested using a 
phytohemagglutinine preparation (PHA) at 1 µg/ml. 
4. Results 
 
18 patients were identified with anti-rabies levels ≤ 0.5 IU/ml after 4 doses of rabies 
vaccine given as a post-exposure prophylaxis. 12 could be contacted and 9 subjects 
accepted to take part in the study. Demographic details of these subjects are 
summarized in table 1.  
 
4.1 Medical history and clinical examination. 
 All rPEP non-responders except subject NR6 had unremarkable medical 
histories and physical examinations. Subject NR6 had been hospitalized several times 
between 2004 and 2008 for diarrhea of unknown etiology and weight loss. At the time 
she received her rPEP in 2008, she was undernourished with a BMI of 17 kg/m2. In 
addition she had an anemia and an iron deficiency. Her current clinical examination 
was normal and she was in a good general condition. Her BMI was 18.5 kg/m2.  
 
4.2 rPEP schedule details 
 No subject had received rabies pre-exposure prophylaxis. All subjects had 
received a human rabies immunoglobulin (HRIG) after exposure. The NR3 and NR8 
started their rPEP schedule outside of Switzerland. All subjects except NR3 received 
the Essen regimen for their rPEP. The NR3 received 4 injections following the Thai 
Red Cross Society regimen that consists in 2-site intradermal injections on days 0, 3, 
and 7 and 1 intradermal injection on days 28 and 90. The NR6 with the past history of 
malnourishment required 5 injections to achieve an acceptable rabies antibody titer 
(2.5 IU/ml). On day 187, her rabies antibody titer fell to 0.3 IU/ml and she received 
two additional vaccine doses. On day 353, she had a rabies antibody titer of 5.4 
IU/ml.  
 
 4.3 Paraclinical investigations 
 All subjects had a normal full blood count and a negative HIV test. Results of 
the PBMC counts and immunoglobulin levels are shown in Table 2. Values are 
normal in all our subjects except for the CD8 T cell numeration for the NR9 and the 
IgG3 level for 5 subjects. These results do not suggest any immunodeficiency for any 
of the subjects. The humoral response to other vaccines is summarized in Table 3. 
The results show a good response to the tetanus vaccine (antibody titer > 0.1 IU/ml) 
in all subjects. Five subjects had received in the past a hepatitis B vaccination. Three 
subjects were tested for their response to the hepatitis B vaccine and the anti-HBs 
levels were detectable for 2 of them. Three subjects accepted to receive a 
pneumococcal vaccination. Unfortunately, further tests showed that those subjects had 
already an adequate antibody level to at least 4 serotypes before the vaccination. This 
element made the evaluation of their response to the pneumococcal vaccination non 
interpretable. However, we could observe a significant improvement of their antibody 
titers after the vaccination. 
 
4.4 Assessment of cellular immune response 
 Results of the PBMC proliferation assay stimulated with MM (memorix mix 
antigen including TT, PPD and candida mannan) and PHA (phytohemagglutinine) 
showed no significant difference between the subjects and the 2 control groups. 
 The results of the lymphocyte proliferation assays done with the 3 different 
concentrations of rabies antigens are presented in figure 1. The results show the 
absence of lymphocyte proliferation in the negative control group. The response of 
subject NC2 can be interpreted as an outlier on the basis of the Grubb test. The 
lymphocyte proliferation after stimulation with 2.5 and 25 mIU/ml was significantly 
higher in the non-responders than in the negative control group, the Z score obtained 
with a Mann Whitney test at the doses 2.5 and 25 were at -3.0741 (U=3, p =0.00214) 
and -2.5861 (U=8, p=0.0096) respectively. Finally the positive control group had a 
significantly better response than the non-responder group at the dose of 25 [mIU/ml] 
with a Z-Score obtained with a Mann Whitney test at 2.0252 (U=10, p=0.04236). 
  The NR6 subject mentioned above with a significant clinical history of past 
digestive problems and malnutrition had a particularly poor response in this 
lymphocyte proliferation assay. The non-responders NR8 and NR9 could be included 
in the study before reaching an adequate antibody response, and samples of PBMC 
could be obtained before and after receiving additional vaccine doses. The results of 
the lymphocyte proliferation assay of these 2 subjects are presented in figure 2. The 
results show a significant increase of the lymphocyte proliferation for the subject NR8 
only after the 5th vaccine dose. The rabies antibody level value measured at the 
second PBMC sample increased significantly also only for the subject NR9 after the 
5th vaccine dose (NR8 = 1.0 IU/ml, NR9 = 7.0 IU/ml). 
 A correlation could be established between the cellular response in the 
lymphocyte proliferation assay and the anti-rabies antibody levels (Figure 3) with a 
correlation coefficient r of 0.7899 (p = 0.000774).  
 
 
 
 
5. Discussion and conclusion 
 In 2010 the WHO and the CDC recommended for rPEP to reduce the number 
of vaccine doses from 5 to 4 doses and to abandon the serological verification on day 
21 after the beginning of the vaccination schedule. A previous study of our group 
showed however that 6,7% of potentially rabies exposed subjects did not develop an 
appropriate antibody level after 4 doses of rPEP. 
 
 In this study we verified if such subjects with poor humoral response to a 
rPEP had any evidence of an immunodeficiency. We evaluated our subjects very 
thoroughly by performing an in depth anamnesis, a clinical examination and the 
laboratory investigations which are usually recommended for the workup of a 
suspected immunodeficiency.xiii Our results show that 8/9 of our rPEP non-responders 
were most probably fully immunocompetent. Only one subject was possibly 
immunodeficient at the time of the rPEP administration, because of a history of 
significant malnutrition. Physical examination, numeration of immune cells and 
assessment of immunoglobulin levels were however normal in all subjects, except for 
the CD8 T-cell numeration for the NR9 and the IgG3 level for 5 subjects. In addition 
we didn’t identify any abnormal response to other vaccines, such as the tetanus, 
hepatitis B and pneumococcal vaccines. 
 Then we investigated the cellular immune response to rabies antigen. It could 
indeed have been postulated that patients with poor humoral response develop 
possibly a strong cellular immune response, which could have been protective. Our 
results show however a correlation between the level of the humoral and the cellular 
immune response. 
 
 Our results suggest that a 4 dose intramuscular rPEP elicits in some patients a 
relatively poor humoral and cellular response, even in the absence of any sign of 
immunosuppression. Cases of rPEP failures with subsequent deaths have been 
reported in other publications. xiv, xv These facts legitimate some interrogations about 
the rPEP schedules currently in use. It is indeed of concern that some rabies-exposed 
subjects are not fully protected with the currently WHO-recommended prophylaxis, 
considering that rabies is an invariably letal disease. 
 The currently WHO-recommended prophylaxis has been adopted since 2010 
and followed a complete literature review conducted by the Advisory Committee on 
Immunization Practices (ACIP) from the CDC.xvi This meta-analysis has included, 
inter alia, studies covering: human rPEP evaluation (11), animal rPEP evaluation (7), 
animal rabies pre expositional prophylaxis (8), Human pre expositional 
immunogenicity (12) and human post expositional immunogenicity (4). Those 4 last 
studies identified are the most related to our study because they documented the 
antibody response following a rPEP administration. Only one of them was a large-
scale study that included 242 healthy veterinary students who mostly received an anti-
rabies vaccine that has never been marketed.xvii Among other studies included, only 
three had been carried out in real-life conditions and using the Essen regimen.iii xviii 
The third one was a pediatric study. xix  
 For the reasons set above, further real life condition studies about rabies post 
expositional immunogenicity should be considered to conclude on the most 
appropriate rPEP schedule. It could also be interesting to evaluate in details the 
humoral and cellular immune responses after intradermic rPEP, which is currently in 
use in many developing countries and which permits to use smaller amount of vaccine 
for rPEP. 
 In conclusion, our study suggests that in addition to the 4 vaccine doses on day 
0, 3, 7, 14 recommended by the WHO, it is useful to do a serologic test on day 21 to 
identify patients who didn't respond appropriately. Those non-responders should 
receive additional vaccine doses, as it seems that they might not be protected neither 
by their humoral response, nor the cellular immune response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Tables 
Table 1 : Demographic details of the subjects 
Subjects Sex Year 
of 
Birth 
Vaccination (dose, brand, lot no) Days of 
vaccination 
Serology Highest AB titer 
measured  [IU/ml], after 
X no of vaccine doses 
1st 2nd 3rd 4th Day
# 
AB Titer 
IU/ml 
NR1 m 1952 Rabipur, 
397011A 
Rabipur, 
397011A 
Rabipur, 
397011A 
Rabipur, 
397011A 
D0, D3, D7, 
D15 
22 0.2 2.7, 6 doses 
NR2 f 1947 Merieux, 
unknown 
Merieux, 
H1341-4 
Merieux, 
H1287-4 
Merieux, 
H1267-4 
D0, D3, D7, 
D14 
21 0.4 5.2, 5 doses 
NR3 m 1960 Rabipur*, 
unknown 
Rabipur*, 
unknown 
Rabipur*, 
unknown 
Rabipur*, 
unknown 
D0, D0, D3, 
D3, D7 
30 0.5 0.5, 5 doses 
NR4 m 1987 Rabipur, 
CMA 
Merieux, 
unknown 
Merieux, 
B0001-9 
Merieux, 
B0001-9 
D0, D3, D7, 
D14 
23 0.5 0.5, 4 doses 
NR5 f 1984 Merieux, 
PMU 
Merieux, 
G1510-4 
Merieux, 
unknown 
Merieux, 
H1287-4 
D0, D3, D7, 
D129 
26 0.3 1.0, 5 doses 
NR6 f 1984 Rabipur, 
CMA 
Rabipur, 
CVMV 
Rabipur, 
CVMV 
Rabipur, 
397011A 
D0, D3, D8, 
D15 
22 0.3 5.4, 7 doses 
NR7 f 1974 Rabipur, 
359011C 
Rabipur, 
378011A 
Rabipur, 
CMA 
Rabipur, 
CMA 
D0, D3, D7, 
D14 
21 0.3 9.9, 5 doses 
NR8 m 1948 Rabipur*, 
unknown 
Rabipur, 
533011A 
Merieux, 
K1323-1 
Merieux, 
K1323-1 
D0, D3, D7, 
D14 
21 0.2 7.0, 7 doses 
NR9 m 1959 Rabipur 
CMA B 
Rabipur 
CVMV 
Rabipur 
CVMV 
Rabipur, 
541011C 
D0, D3, D8, 
D15 
22 0.2 1.0, 5 doses 
*Vaccine doses received abroad; # count starting on the day of the first dose received !!
Table 2 Part 1 : Numeration of Peripheral blood mononuclear cells of the subjects 
 T cell CD4 T-cell CD8 T-cell Monocyte B cell NK cell 
Normal values 780-2240  490-1640  170-880  200-800  80-490  80-690  
Subjects cell/mm3 % cell/mm3 % cell/mm3 % cell/mm3 % cell/mm3 % cell/mm3 % 
NR1 915 45.5 654 32.5 285 14.2 509 25.3 101 5 432 21.5 
NR2 1078 54.5 800 40.4 247 12.5 448 22.6 224 11.3 137 6.9 
NR3 1601 59.9 937 35 641 24 364 13.6 290 10.9 383 14.3 
NR4 1563 64.3 886 36.4 611 25.1 288 11.8 321 13.2 185 7.6 
NR5 1295 63.9 951 46.9 320 15.8 323 15.9 203 10 150 7.4 
NR6 1274 67.6 840 44.6 402 21.3 323 17.1 136 7.2 116 6.2 
NR7 1237 56.7 674 30.9 476 21.8 461 21.1 159 7.3 271 12.4 
NR8 1158 53.4 775 35.7 397 18.3 330 15.2 247 11.4 381 17.6 
NR9 617 32.7 495 26.2 104 5.5 822 43.5 389 15.3 54 2.8 !
Table 2 Part 2 : Numeration of leucocyte subpopulations 
 Neutrophiles Lymphocytes Monocytes Eosinophiles Basophiles Immature 
granulocytes Normal values 1.8-7.5 40-75 1.5-4.0 25-40 0.2-0.8 2-8 0.05-0.3 1-5 0.01-0.05 0-1 
Subjects G/l % G/l % G/l % G/l % G/l % G/l % 
NR1 4.26 67 1.39 22 0.58 9 0.06 1 0.07 1 0.01 0.2 
NR2 2.67 54 1.56 31 0.49 10 0.19 4 0.07 1 0.01 0.2 
NR3 2.82 47 2.42 40 0.55 9 0.15 3 0.04 1 0.02 0.3 
NR4 2.89 50 2.18 38 0.52 9 0.14 2 0.01 0 0.01 0.2 
NR5 3.45 62 1.67 30 0.33 6 0.11 2 0.02 0 0.01 0.2 
NR6 3.64 65 1.49 27 0.34 6 0.07 1 0.05 1 0.03 0.5 
NR7 3.25 59 1.73 31 0.52 9 0.03 1 0.01 0 0.01 0.2 
NR8 3 53 1.9 34 0.46 8 0.27 5 0.02 0 0.01 0.2 
NR9 6.22 78 0.93 12 0.71 9 0.1 1 0.01 0 0.01 0.1 
 Table 2 Part 3 : Immunoglobulin levels 
 IGG IGG1 IGG2 IGG3 IGG4 IGA IGM 
Normal values 7-14.5 5.2-12.7 1.43-5.6 0.28-1.05 0.011-1.04 0.71-4.07 0.34-2.41 
Subjects g/l g/l g/l g/l g/l g/l g/l 
NR1 12.2 8.78 3.46 0.21 0.423 1.07 1.14 
NR2 10.1 5.04 4.6 0.22 0.941 0.87 2.66 
NR3 10.3 5.27 4.54 0.55 0.784 3.2 0.79 
NR4 11.4 7.25 5.82 0.66 1.04 1.43 1.59 
NR5 9.05 5.19 3.38 0.35 0.04 1 0.88 
NR6 8.79 5.71 2.53 0.24 0.144 1.26 1.76 
NR7 11 5.75 4.87 0.38 0.347 2.16 1.05 
NR8 10.9 8.02 2.33 0.27 0.056 2.08 0.89 
NR9 10.9% 7.24% 2.54% 0.27% 0.352% 2.15% 0.85%
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Table 3 : Antibody response to other vaccines 
 Hepatitis B vaccination Tetanic vaccination Pneumococcal # 
Subjects Time since 
baseline 
vaccination 
Additional 
vaccine dose 
given at time 
of study 
Anti 
HBs* 
[mIU/ml] 
Time since 
baseline 
vaccination 
Tetanus 
AB level· 
[U/ml] 
Number of serotypes ¢ 
pre 
vaccination 
post 
vaccination 
NR1 >5 years No NT 15 years 1.88 NT NT 
NR2 Never done No NT 2 years 2.58 4 6 
NR3 14 years No NT 7 years 2.52 6 6 
NR4 5 years No >10 3 months 1.39 NT NT 
NR5 >5 years Yes NT 4 years 1.45 NT NT 
NR6 14 years No <10 7 years 1.18 NT NT 
NR7 6 years No 2893 11 years 2.12 NT NT 
NR8 Unknown No NT Unknown 2.65 5 5 
NR9 Never done No NT 1 month 2.14 NT NT 
 * Undetectable anti-HBs levels were considered as abnormal · A tetanus antibody level < 0.1 U/ml was 
considered as abnormal # in our subjects who accepted to receive a pneumocoque vaccination, a 23 
valent Polysaccharide pneumococcal vaccination has been administred and 6 serotypes have been tested 
the day they joined the study and 4 weeks after their injection. ¢ A serotype >0.3  [mg/l] is considered as 
accurate NT = non tested 
7. Figures 
Figure 1 : Results of the Peripheral blood mononuclear (PBMC) proliferation assays. 
PBMC were stimulated with of the Flury-LEP vaccine strain (Rabipur, Novartis) at 
concentrations of 0.25, 2.5, 25 mIU/ml. 
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Figure'2!:!Results!of!the!Peripheral blood mononuclear (PBMC) proliferation assays 
of the non-responders NR8 and NR9. A PBMC proliferation assays was performed on 
these 2 subjects before they reached an antibody level of 0,5 IU/ml (left) and after 
they had received an additional dose of rabies vaccine and had reached an antibody 
level >0,5 IU/l (right). Results show a significant increase of the PBMC proliferation 
for subject NR8 only. This result can be explained by the fact that the rabies antibody 
level increased only for the subject NR8 : NR8 = 7.0 [IU/ml], NR9 = 1.0 [IU/ml].!
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Figure 3 : Correlation between rabies antibody levels and PBMC proliferation index. 
The results show a significant linear correlation (R = 0.79 by the Pearson test)- 
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